Q&A – Product launch

2cureX is happy to receive a number of questions and comments from our present and from potential future shareholders.

With the present Questions & Answers (Q&A) section, we would like to make these questions and their answers publicly available. Additional questions/comments should be mailed to info@2cureX.com.

What is the status of your relationship with Docrates in Helsinki?

Posted on 2021-06-11
2cureX established a collaboration with Docrates in 2019 with the purpose of testing IndiTreat on metastatic colorectal cancer (mCRC) patients. That was an early-stage collaboration as we did not have the clinical evidence to support the product at that point. As part of the collaboration, we received 5 patient samples from Docrates, two of these were mCRC, and one each of Cancer of Unknown Primary (CUP), Head & Neck, and ovarian cancer.

With the publication of the successful TICC trial results we are now offering the test widely across Europe to major hospitals and cancer centers.

Do you see changes in the competitive landscape?

Posted on 2021-06-11
We are seeing an increasing number of institutions and companies engaging in Functional Testing, both in Europe and in the US. 2cureX welcomes new players to move into this space as it will help accelerate the adoption of this new technology in routine clinical practice. We need broad scientific and clinical support to have large international hospitals and health care authorities to embrace this next wave in cancer treatment, and eventually include 3D microtumor testing in treatment guidelines.

Nevertheless, the new stringent regulatory environment coming in force in Europe in 2022 is likely to have a significant impact in the number of commercial players and the availability of their products. At 2cureX we are fully focused in preparing for this new regulatory scenario.

What preparations have been done to prepare for the launch of IndiTreat®?

Posted on 2019-12-05
To prepare for launch, 2cureX has continuously interacted with the target customer segments and mapped their workflow, needs and purchasing pattern. The focus has been on Germany, UK and the Nordics as well as some markets that could be included in the next phase of the launch. 2cureX has also engaged advisors and experts in the field of market access to help optimize the launch strategy.

Is 2cureX discussing the implementation of the test with hospitals in launch countries?

Posted on 2019-11-20
Yes, 2cureX is in direct contact with key opinion leaders (KOL) at university hospitals, large regional clinics, specialized oncology clinics and diagnostic commercial labs. With several of these clinics 2cureX is in an advanced dialogue regarding the implementation of IndiTreat. The customer interactions and dialogue with commercial labs have provided valuable market insights that will benefit the launch.

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

December 7, 2021

CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)

Read more

December 9, 2021

2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)

Read more

January 20, 2022

2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)

Read more

February 24, 2022

Year-End Report 2021

View previous reports

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs